ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
3485 articles with ACCESSWIRE
-
Abivax Announces the Success of Its Oversubscribed Capital Increase of EUR 28m at Market Price
10/29/2020
Subscribed by top-tier U.S. and European biotech investors (12 investors in total, 55% of funds raised from European investors, 45% from the U.S.)
-
Sanara MedTech Inc. Announces Uplisting to The Nasdaq Capital Market
10/29/2020
Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc., a provider of wound and skin care products and virtual consult services dedicated to improving patient outcomes, announced that it has received approval to list its common stock on The Nasdaq Capital Market.
-
Wuhan General Group Updates on University of Pretoria Research Collaboration for Psilocybin Magic Mushroom Clinical Trials
10/29/2020
WUHAN GENERAL GROUP, INC., a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update
-
Interim Management Statement Q3 2020 of Molecular Partners: Emergence of New Opportunities and Strong Platform Validation of DARPin® Therapeutics
10/29/2020
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced its interim management statement for the period ending September30, 2020.
-
Halberd Corp. Development Efforts Transcend Covid-19 Prevention, Diagnostics & Therapeutics
10/29/2020
Halberd Corporation provided insight concerning its strategic plans beyond developing unique antibodies which form the basis of their current all-out efforts to generate products and processes to prevent, diagnose and treat Covid-19.
-
Angle PLC Announces Interim Results
10/29/2020
ANGLE plcANGLE plcANGLE plcANGLE plc, a world leading liquid biopsy company, announces its unaudited interim financial results for the six months ended 30 June 2020.
-
Hancock Jaffe Reports Successful Completion of First CoreoGraft Heart Bypass Surgery
10/28/2020
Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that the first heart bypass surgery in HJLI's first-in-human CoreoGraft study was successfully completed and the patient has been discharged from the hospital.
-
Avinger to Announce Third Quarter 2020 Results on November 10, 2020
10/28/2020
Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease, announced that it will release its financial results for the third quarter 2020 after the close of trading on Tuesday, November 10, 2020.
-
Applied UV, Inc. Announces Exclusive Licensing and Joint Development Agreement with Axis Lighting to Commercialize LED-based Technologies in UV-C Devices to Inactivate Pathogens on Surfaces in the Hospital Market
10/28/2020
Applied UV, Inc., an infection prevention technology company that applies the power of ultra violet C light utilizing its patented devices to destroy pathogens safely, thoroughly, and automatically, announced that its subsidiary, SteriLumen, Inc., and Axis Lighting, Inc. of Quebec, Canada, have entered into an exclusive license and joint development agreement.
-
Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19
10/28/2020
Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19
-
XPhyto Announces RT-PCR Test for Point-of-Care COVID-19 Detection
10/28/2020
XPhyto Therapeutics Corp., a next-generation bioscience accelerator, is pleased to announce that its exclusive diagnostic partner, 3a-Diagnostics GmbH, is developing a reverse transcription polymerase chain reaction kit targeting COVID-19 diagnostic results in 25 minutes.
-
Tetra Bio Pharma Announces Divestiture of Lumiera Health Innovation Inc.
10/28/2020
Tetra Bio-Pharma Inc. today announces that it has completed the divestiture of Lumiera Health Innovation Inc. ("Lumiera"), its subsidiary, to Mondias Natural Products Inc. (TSXV: NHP) ("Mondias ") as previously announced.
-
Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020
10/28/2020
Pieris Pharmaceuticals, Inc. today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, 2020 at 8:00 AM EST to discuss financial results and provide a corporate update.
-
Ovation Science Secures Listing for DermSafe on Amazon.ca to Increase Direct to Canadian Consumer Purchases
10/28/2020
Ovation Science Inc. is pleased to announce that its DermSafe® Hand Sanitizer Lotion is listed on Amazon.ca. The product listing offered on Amazon.ca and can be purchased by both regular and prime members.
-
ENDRA Life Sciences Issued Fifth European Patent that Protects its TAEUS(R) Platform for Imaging Biological Tissue Structures
10/28/2020
ENDRA Life Sciences Inc. announces it has been issued European Patent EP 3 294 142 B1 (the '142 patent) from the European Patent Office
-
MorphoSys AG Raises its Financial Guidance for the Full Year 2020
10/27/2020
MorphoSys AG ; Prime Standard Segment; MDAX & TecDAX; announces an increase in its financial guidance for the financial year 2020 after preliminary completion of the latest evaluation of MorphoSys' financial performance.
-
Hancock Jaffe Submits VenoValve Pre-IDE Filing to FDA
10/27/2020
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted a Pre-IDE filing to the U.S. Food and Drug Administration and has requested a meeting with the FDA to discuss a few key matters in advance of the filing of its IDE application for the VenoValve U.S. pivotal trial.
-
Viveve Launches New Clinical Advisory Board in Urinary Incontinence
10/27/2020
Preeminent urology and urogynecology experts to help guide and advance the companys pivotal U.S. PURSUIT trial in Stress Urinary Incontinence
-
ITOCO Completes Immutable Virus Test Result Scure Web Application.
10/27/2020
ITOCO INC. has successfully developed and deployed a secure software-as-a-service web-based application for administering the Immutable Virus Test Result Verification System and has made it available at ImmutableTest.com.
-
EuMentis Therapeutics Inc. Announces Closing of Series A Financing
10/27/2020
Company focused on development of novel drugs with clinically-validated mechanisms for the treatment of neurodevelopmental and neurodegenerative disorders Lead product candidate, EM-036, has demonstrated superior efficacy in preclinical Autism Spectrum Disorders